Table of Contents Author Guidelines Submit a Manuscript
Experimental Diabetes Research
Volume 2012, Article ID 678381, 9 pages
http://dx.doi.org/10.1155/2012/678381
Research Article

Mannan-Binding Lectin in Diabetic Kidney Disease: The Impact of Mouse Genetics in a Type 1 Diabetes Model

1Department of Endocrinology and Internal Medicine, Aarhus University Hospital and The Medical Research Laboratories, Institute of Clinical Medicine, Faculty of Health Sciences, Aarhus University, 8000 Aarhus C, Denmark
2Center for Renal Translational Medicine, University of California, San Diego/VA Medical System, La Jolla, CA 92093-0711, USA
3Stereology and Electron Microscopy Laboratory, Centre for Stochastic Geometry and Advanced Bioimaging, Aarhus University Hospital, 8000 Aarhus C, Denmark
4Department of Medical Microbiology and Immunology, Faculty of Health Sciences, Aarhus University, 8000 Aarhus C, Denmark

Received 29 December 2011; Revised 31 January 2012; Accepted 1 February 2012

Academic Editor: Daisuke Koya

Copyright © 2012 Jakob Appel Østergaard et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. Danish Society of Nephrology, Annual report 2010—Danish Nephrology Registry, 2011.
  2. European Renal Association, European Dialysis and Transplant Association. ERA-EDTA Registry—Annual Report 2009, 2011.
  3. United States Renal Data Systems, 2011 USRDS Annual Data Report, 2011.
  4. S. McDonald, L. Excell, and B. Livingston, ANZDATA Registry 2010 - The 33rd Report, 2011.
  5. S. L. White, S. J. Chadban, S. Jan, J. R. Chapman, and A. Cass, “How can we achieve global equity in provision of renal replacement therapy?” Bulletin of the World Health Organization, vol. 86, no. 3, pp. 229–237, 2008. View at Publisher · View at Google Scholar · View at Scopus
  6. A. R. Andersen, J. S. Christiansen, J. K. Andersen et al., “Diabetic nephropathy in type 1 (insulin-dependent) diabetes: an epidemiological study,” Diabetologia, vol. 25, no. 6, pp. 496–501, 1983. View at Google Scholar · View at Scopus
  7. D. J. Ballard, L. L. Humphrey, L. J. Melton et al., “Epidemiology of persistent proteinuria in type II diabetes mellitus. Population-based study in Rochester, Minnesota,” Diabetes, vol. 37, no. 4, pp. 405–412, 1988. View at Google Scholar · View at Scopus
  8. P. Hovind, L. Tarnow, P. Rossing et al., “Predictors for the development of microalbuminuria and macroalbuminuria in patients with type 1 diabetes: inception cohort study,” British Medical Journal, vol. 328, no. 7448, pp. 1105–1108, 2004. View at Google Scholar · View at Scopus
  9. A. Kofoed-Enevoldsen, K. Borch-Johnsen, S. Kreiner, J. Nerup, and T. Deckert, “Declining incidence of persistent proteinuria in type I (insulin-dependent) diabetic patients in Denmark,” Diabetes, vol. 36, no. 2, pp. 205–209, 1987. View at Google Scholar · View at Scopus
  10. A. S. Krolewski, J. H. Warram, and A. R. Christlieb, “The changing natural history of nephropathy in type I diabetes,” American Journal of Medicine, vol. 78, no. 5, pp. 785–794, 1985. View at Google Scholar · View at Scopus
  11. M. Bojestig, H. J. Arnqvist, G. Hermansson, B. E. Karlberg, and J. Ludvigsson, “Declining incidence of nephropathy in insulin-dependent diabetes mellitus,” New England Journal of Medicine, vol. 330, no. 1, pp. 15–18, 1994. View at Publisher · View at Google Scholar · View at Scopus
  12. K. Earle, J. Walker, C. Hill, and G. Viberti, “Familial clustering of cardiovascular disease in patients with insulin- dependent diabetes and nephropathy,” New England Journal of Medicine, vol. 326, no. 10, pp. 673–677, 1992. View at Google Scholar · View at Scopus
  13. E. R. Seaquist, F. C. Goetz, S. Rich, and J. Barbosa, “Familial clustering of diabetic kidney disease. Evidence for genetic susceptibility to diabetic nephropathy,” New England Journal of Medicine, vol. 320, no. 18, pp. 1161–1165, 1989. View at Google Scholar · View at Scopus
  14. J. Østergaard, T. K. Hansen, S. Thiel, and A. Flyvbjerg, “Complement activation and diabetic vascular complications,” Clinica Chimica Acta, vol. 361, no. 1-2, pp. 10–19, 2005. View at Publisher · View at Google Scholar · View at Scopus
  15. T. K. Hansen, L. Tarnow, S. Thiel et al., “Association between mannose-binding lectin and vascular complications in type 1 diabetes,” Diabetes, vol. 53, no. 6, pp. 1570–1576, 2004. View at Publisher · View at Google Scholar · View at Scopus
  16. M. A. Kaunisto, L. Sjolind, R. Sallinen et al., “Elevated MBL concentrations are not an indication of association between the MBL2 gene and type 1 diabetes or diabetic nephropathy,” Diabetes, vol. 58, no. 7, pp. 1710–1714, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. M. Saraheimo, C. Forsblom, T. K. Hansen et al., “Increased levels of mannan-binding lectin in type 1 diabetic patients with incipient and overt nephropathy,” Diabetologia, vol. 48, no. 1, pp. 198–202, 2005. View at Publisher · View at Google Scholar · View at Scopus
  18. P. Hovind, T. K. Hansen, L. Tarnow et al., “Mannose-binding lectin as a predictor of microalbuminuria in type 1 diabetes: an inception cohort study,” Diabetes, vol. 54, no. 5, pp. 1523–1527, 2005. View at Publisher · View at Google Scholar · View at Scopus
  19. T. K. Hansen, M. A. Gall, L. Tarnow et al., “Mannose-binding lectin and mortality in type 2 diabetes,” Archives of Internal Medicine, vol. 166, no. 18, pp. 2007–2013, 2006. View at Publisher · View at Google Scholar · View at Scopus
  20. J. Østergaard, S. Thiel, M. Gadjeva, T. K. Hansen, R. Rasch, and A. Flyvbjerg, “Mannose-binding lectin deficiency attenuates renal changes in a streptozotocin-induced model of type 1 diabetes in mice,” Diabetologia, vol. 50, no. 7, pp. 1541–1549, 2007. View at Publisher · View at Google Scholar · View at Scopus
  21. M. D. Breyer, E. Bottinger, F. C. Brosius III et al., “Mouse models of diabetic nephropathy,” Journal of the American Society of Nephrology, vol. 16, no. 1, pp. 27–45, 2005. View at Publisher · View at Google Scholar · View at Scopus
  22. M. Ruseva, M. Kolev, F. Dagnaes-Hansen et al., “Mannan-binding lectin deficiency modulates the humoral immune response dependent on the genetic environment,” Immunology, vol. 127, no. 2, pp. 279–288, 2009. View at Publisher · View at Google Scholar · View at Scopus
  23. S. R. Dunn, Z. Qi, E. P. Bottinger, M. D. Breyer, and K. Sharma, “Utility of endogenous creatinine clearance as a measure of renal function in mice,” Kidney International, vol. 65, no. 5, pp. 1959–1967, 2004. View at Publisher · View at Google Scholar · View at Scopus
  24. A. S. Lihn, J. M. Bruun, G. He, S. B. Pedersen, P. F. Jensen, and B. Richelsen, “Lower expression of adiponectin mRNA in visceral adipose tissue in lean and obese subjects,” Molecular and Cellular Endocrinology, vol. 219, no. 1-2, pp. 9–15, 2004. View at Publisher · View at Google Scholar · View at Scopus
  25. S. B. Gurley, S. E. Clare, K. P. Snow, A. Hu, T. W. Meyer, and T. M. Coffman, “Impact of genetic background on nephropathy in diabetic mice,” American Journal of Physiology, vol. 290, no. 1, pp. F214–F222, 2006. View at Publisher · View at Google Scholar · View at Scopus
  26. Z. Qi, H. Fujita, J. Jin et al., “Characterization of susceptibility of inbred mouse strains to diabetic nephropathy,” Diabetes, vol. 54, no. 9, pp. 2628–2637, 2005. View at Publisher · View at Google Scholar · View at Scopus
  27. T. K. Hansen, S. Thiel, S. T. Knudsen et al., “Elevated levels of mannan-binding lectin in patients with type 1 diabetes,” Journal of Clinical Endocrinology and Metabolism, vol. 88, no. 10, pp. 4857–4861, 2003. View at Publisher · View at Google Scholar · View at Scopus
  28. T. K. Hansen, C. Forsblom, M. Saraheimo et al., “Association between mannose-binding lectin, high-sensitivity C-reactive protein and the progression of diabetic nephropathy in type 1 diabetes,” Diabetologia, vol. 53, no. 7, pp. 1517–1524, 2010. View at Publisher · View at Google Scholar · View at Scopus
  29. J. A. Østergaard, S. Thiel, T. K. Hansen, R. Rasch, and A. Flyvbjerg, “Comment on: Lin et al. (2010) immune cell-derived c3 is required for autoimmune diabetes induced by multiple low doses of streptozotocin. Diabetes;59: 2247–2252,” Diabetes, vol. 60, no. 1, pp. e7–e8, 2011. View at Publisher · View at Google Scholar
  30. M. E. Cooper, D. Vranes, S. Youssef et al., “Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental diabetes,” Diabetes, vol. 48, no. 11, pp. 2229–2239, 1999. View at Publisher · View at Google Scholar · View at Scopus
  31. K. Ichinose, Y. Maeshima, Y. Yamamoto et al., “Antiangiogenic endostatin peptide ameliorates renal alterations in the early stage of a type 1 diabetic nephropathy model,” Diabetes, vol. 54, no. 10, pp. 2891–2903, 2006. View at Publisher · View at Google Scholar
  32. L. J. N. Jensen, L. Denner, B. F. Schrijvers, R. G. Tilton, R. Rasch, and A. Flyvbjerg, “Renal effects of a neutralising RAGE-antibody in long term streptozotocin-diabetic mice,” Journal of Endocrinology, vol. 188, no. 3, pp. 493–501, 2006. View at Publisher · View at Google Scholar · View at Scopus
  33. D. C. Kilpatrick, I. Downing, S. L. MacDonald, and M. L. Turner, “MBL really binds to healthy human cells!,” Scandinavian Journal of Immunology, vol. 66, no. 5, pp. 599–600, 2007. View at Publisher · View at Google Scholar · View at Scopus
  34. J. Fortpied, D. Vertommen, and E. van Schaftingen, “Binding of mannose-binding lectin to fructosamines: a potential link between hyperglycaemia and complement activation in diabetes,” Diabetes/Metabolism Research and Reviews, vol. 26, no. 4, pp. 254–260, 2010. View at Publisher · View at Google Scholar · View at Scopus
  35. J. Acosta, J. Hettinga, R. Fluckiger et al., “Molecular basis for a link between complement and the vascular complications of diabetes,” Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 10, pp. 5450–5455, 2000. View at Publisher · View at Google Scholar · View at Scopus
  36. X. Qin, A. Goldfine, N. Krumrei et al., “Glycation inactivation of the complement regulatory protein CD59: a possible role in the pathogenesis of the vascular complications of human diabetes,” Diabetes, vol. 53, no. 10, pp. 2653–2661, 2004. View at Publisher · View at Google Scholar · View at Scopus
  37. H. F. Weisman, T. Bartow, M. K. Leppo et al., “Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis,” Science, vol. 249, no. 4965, pp. 146–151, 1990. View at Google Scholar · View at Scopus
  38. M. Moller-Kristensen, W. Wang, M. Ruseva et al., “Mannan-binding lectin recognizes structures on ischaemic reperfused mouse kidneys and is implicated in tissue injury,” Scandinavian Journal of Immunology, vol. 61, no. 5, pp. 426–434, 2005. View at Publisher · View at Google Scholar
  39. M. C. Walsh, T. Bourcier, K. Takahashi et al., “Mannose-binding lectin is a regulator of inflammation that accompanies myocardial ischemia and reperfusion injury,” Journal of Immunology, vol. 175, no. 1, pp. 541–546, 2005. View at Google Scholar · View at Scopus